Paul Nathan
Mount Vernon Hospital(GB)
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Renal cell carcinoma treatment, Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Cutaneous Melanoma Detection and Management
Most-Cited Works
- → Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib(2014)2,622 cited
- → Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma(2012)2,130 cited
- → Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma(2013)1,903 cited
- → Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma(2014)1,843 cited
- → Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial(2015)1,372 cited
- → Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group(2012)1,342 cited